Michelle Dipp holds a Bachelor of Medicine and Bachelor of Surgery (1995-2005) from the University of Oxford Medical School. In 2001, Michelle received a Doctor of Philosophy in Human Physiology from the University of Oxford. In 2005, she completed her post-doctoral research at the Department of Physiology and the John Radcliffe Hospital. Michelle was able to participate in extensive research as can be seen through her Google Scholar citations.

Michelle began her investment career at the Wellcome Trust after completing her medical training. 

Michelle Dipp


Michelle Dipp, MD PhD is Co-Founder and Managing Partner at Biospring Partners and has over a decade of private equity and venture capital expertise in life sciences. She currently serves on the Board of Abzena.


Prior to launching Biospring Partners, Michelle was a Managing Director at General Atlantic, a global growth equity firm based in New York. While at General Atlantic, Michelle launched their first life sciences investment platform and served as a member of the life sciences investment committee. Michelle served as a Board Observer for Ginkgo BioWorks and as a board member for PathAI and Immunocore.


Michelle was a Co-Founder and former General Partner of Longwood Fund, a leading healthcare investment firm based in Boston. As a General Partner in Longwood Funds I, II, III, and IV, Michelle co-founded several of Longwood Fund portfolio companies, where she held senior management and board positions, including Chairman of Axial Biotherapeutics and CEO and Chairman of OvaScience, Inc. Michelle served on the board of Colorescience and as a board observer of Bicycle Therapeutics and Pulmocide Ltd.


Before joining Longwood, she was GlaxoSmithKline’s (GSK) Senior Vice President of the Centre of Excellence for External Drug Discovery (CEEDD), GSK’s global business development group. Michelle also served as Vice President of Corporate Development at Sirtris Pharmaceuticals, Inc. (acquired by GSK).  Michelle’s outstanding leadership has earned her acknowledgements including by Fortune where she was named a 40 under 40 in 2015.

Current Projects

Michelle currently serves on the Trustee Advisory Board for Beth Israel Deaconess Medical Center; Advisory Board for the Women’s Foundation of Boston; Board of Directors for Life Science Cares; Rockefeller University Council; Advisory Council for the American Museum of Natural History; Co-Founding Member of the Bowman Fund, Brasenose College Boat Club, Oxford University; and a member of the World Economic Forum’s Young Global Leaders.


Michelle Dipp MD, PhD - Pulmonary Hypertension and Hypoxic Pulmonary Vasoconstriction: The Role of Calcium Sensitization

Michelle Dipp published her first book in July 2009. This book explores the role of calcium sensitization in pulmonary hypertension and hypoxic pulmonary vasoconstriction. The book is available for purchase on Amazon.

Michelle Dipp MD, PhD - Featured Chapter in Hypoxic Pulmonary Vasoconstriction: Cellular and Molecular Mechanisms (Developments in Cardiovascular Medicine, 252)

This book is a complete reference on hypoxic pulmonary vasoconstriction and hypoxia-mediated pulmonary hypertension designed for clinicians to guide and improve clinical treatment and diagnosis of their patients. The book is available for purchase on Amazon.